Advisory panel rejections carry the greatest clout at the FDA

Just how influential are those expert FDA advisory panels? Concept Capital studied 120 votes stretching from 2007 to 2010 and found that the agency followed their recommendations three out of four times. But the FDA is far more likely to be influenced by a rejection than an approval. As Forbes' Matthew Herper notes in an analysis, the agency overruled a no vote only three times. Yes turned out to be an easier decision to overlook.

For investors interested in gaming the approval process, Herper looks at the implications of the analysis on the hopes of scoring an upset approval on Vivus' and Arena's weight drugs, both of which went down to defeat recently in front of a committee distinctly leery of a drug category that has been rife with safety issues. "History says the FDA is not likely to change its mind," notes Herper.

Of course, the agency's rejections often come with a set of instructions for changing its decision. Complete response letters can detail new work that can keep hope alive. Dendreon survived that process after the FDA initially ignored an advisory panel's endorsement of Provenge. Vivus and Arena may soon be working on Plan B.

- here's the report from Forbes

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.